Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates
暂无分享,去创建一个
Franz Jakob | M. Wirth | T. Rachner | G. Baretton | S. Fuessel | K. Erdmann | C. Hamann | F. Jakob | M. Rauner | Claudia Goettsch | Christine Hamann | Lorenz C Hofbauer | C. Goettsch | Kati Erdmann | Manfred P Wirth | Susanne Fuessel | Martina Rauner | Gustavo B Baretton | Sylvia Thiele | Tilman D Rachner | Peggy Benad | P. Benad | S. Thiele | L. Hofbauer
[1] T. Asahara,et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. , 2006, Cancer research.
[2] O. Fromigué,et al. Bisphosphonates Induce Breast Cancer Cell Death In Vitro , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] P. Kantoff,et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Rentsch,et al. Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer. , 2009, Swiss medical weekly.
[5] R. Iozzo,et al. Aberrant expression of the growth factor Wnt-5A in human malignancy. , 1995, Cancer research.
[6] R. Shah,et al. Dickkopf‐1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis , 2008, The Prostate.
[7] P Delmas,et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. , 2000, Cancer research.
[8] H. Moch,et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.
[9] A. Tizzani,et al. Osteoclasts Are Active in Bone Forming Metastases of Prostate Cancer Patients , 2008, PloS one.
[10] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[11] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[12] L. Trümper,et al. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[13] O. MacDougald,et al. Role of wnts in prostate cancer bone metastases , 2006, Journal of cellular biochemistry.
[14] S. Aaronson,et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. , 2005, Cancer research.
[15] N. Oue,et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase , 2010, Oncogene.
[16] F. Saad. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. , 2002, Clinical prostate cancer.
[17] N. Clarke,et al. Osteoblast function and osteomalacia in metastatic prostate cancer. , 1993, European urology.
[18] Y. Yen,et al. Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells , 2010, International journal of cancer.
[19] F. Zhan,et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.
[20] G. Rodan,et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. , 1991, The Journal of clinical investigation.
[21] I. Vermes,et al. Differential effects of bisphosphonates on breast cancer cell lines. , 2007, Cancer letters.
[22] T. Takumi,et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling , 2009, Oncogene.
[23] T. Yoneda,et al. Breast cancer‐derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases , 2008, International journal of cancer.
[24] S. Hayward,et al. Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis , 2008, Oncogene.
[25] J. Eastham,et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. , 2003, The Journal of urology.
[26] C. Logothetis,et al. Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.
[27] A. Potti,et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. , 2004, Cancer.
[28] G. H. Nancollas,et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. , 2006, Bone.
[29] Georg Schett,et al. Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.
[30] A. Silver,et al. The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.